NGNE news

Neurogene Inc. entered an underwriting agreement to sell 3.5 million shares and pre-funded warrants. The offering is intended to raise capital for general corporate purposes.

Neurogene announced 30-month data showing participants significantly gained developmental milestones without plateauing or loss, demonstrating a durable therapeutic effect. This positive clinical progress for a rare disease treatment could boost investor sentiment as the company advances toward regi…

Neurogene Inc. successfully completed enrollment in its Embolden registrational trial for NGN-401, dosing 25 participants (exceeding the 20-patient target) with no safety concerns reported. Topline data is expected in the second half of 2027, potentially supporting a planned Biologics License Applic…